Pfizer Settles Patent Disputes, Extends VYNDAMAX Exclusivity To 2031
28/4 18:06
(RTTNews) - Pfizer Inc. (PFE) on Tuesday said it has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla over patent litigation related to Vyndamax, its treatment for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)....